{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:50:25Z","timestamp":1792417825524,"version":"4.4.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"\n Importance<\/jats:title>\n Arterial hypertension is associated with an increased incidence of epilepsy. Results from animal studies suggest that angiotensin receptor blocker (ARB) therapy could inhibit epileptic seizures. However, there is a lack of clinical data to support the use of ARB therapy in humans.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess whether ARB therapy is associated with a decreased incidence of epilepsy in patients with hypertension.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study obtained data from the Disease Analyzer database (IQVIA) on patients aged 18 years or older who had hypertension and at least 1 antihypertensive drug prescription. Patients were treated at 1274 general practices between January 2010 and December 2020 in Germany. Data were available for 1\u202f553\u202f875 patients who had been prescribed at least 1 antihypertensive drug. Patients diagnosed with epilepsy before or up to 3 months after the index date were excluded. A total of 168\u202f612 patients were included in propensity score matching. Patients treated with 1 of 4 antihypertensive drug classes (\u03b2-blockers, ARBs, angiotensin-converting enzyme inhibitors, and calcium channel blockers [CCBs]) were matched to each other using propensity scores.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome of the study was the incidence of epilepsy associated with ARB therapy compared with other antihypertensive drug classes. Cox regression models were used to study the association between the incidence of epilepsy and ARBs compared with all other antihypertensive drug classes as a group.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study included a total of 168\u202f612 patients, with 42\u202f153 in each antihypertensive drug class. The mean [SD] age of patients was 62.3 [13.5] years, and 21 667 (51.4%) were women. The incidence of epilepsy within 5 years was lowest among patients treated with ARBs (0.27% at 1 year, 0.63% at 3 years, 0.99% at 5 years) and highest among patients receiving \u03b2-blockers and CCBs (0.38% for both \u03b2-blockers and CCBs at 1 year; 0.91% for \u03b2-blockers and 0.93% for CCBs at 3 years; \u03b2-blockers, 1.47%; and CCBs, 1.48% at 5 years). Angiotensin receptor blocker therapy was associated with a significantly decreased incidence of epilepsy (hazard ratio, 0.77; 95% CI, 0.65-0.90) compared with the other drug classes as a group.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients with hypertension, ARB therapy was associated with a significantly decreased incidence of epilepsy. The findings suggest antihypertensive drugs could be used as a novel approach for preventing epilepsy in patients with arterial hypertension.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2022.3413","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T11:35:32Z","timestamp":1666006532000},"page":"1296","source":"Crossref","is-referenced-by-count":40,"title":["Association Between Angiotensin Receptor Blocker Therapy and Incidence of Epilepsy in Patients With Hypertension"],"prefix":"10.1001","volume":"79","author":[{"given":"Corinna","family":"Doege","sequence":"first","affiliation":[{"name":"Department of Pediatric Neurology, Center of Pediatrics and Adolescent Medicine, Central Hospital Bremen, Bremen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Luedde","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Christian-Albrechts-University of Kiel, Kiel, Germany"},{"name":"Cardiology Practice Bremerhaven, Bremerhaven, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[{"name":"Epidemiology, IQVIA, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"noi220064r1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1684\/epd.2015.0751","article-title":"The natural history and prognosis of epilepsy.","volume":"17","author":"Beghi","year":"2015","journal-title":"Epileptic Disord"},{"issue":"4","key":"noi220064r2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/epi.1993.34.issue-4","article-title":"Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy.","volume":"34","year":"1993","journal-title":"Epilepsia"},{"issue":"9516","key":"noi220064r3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(06)68477-8","article-title":"Adult epilepsy.","volume":"367","author":"Duncan","year":"2006","journal-title":"Lancet"},{"issue":"22","key":"noi220064r4","doi-asserted-by":"publisher","first-page":"e2035","DOI":"10.1212\/WNL.0000000000006564","article-title":"Identification of patients who will not achieve seizure remission within 5 years on AEDs.","volume":"91","author":"Hughes","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"noi220064r5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs.","volume":"9","author":"Bialer","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"noi220064r6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study.","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"9","key":"noi220064r7","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s10072-019-03913-4","article-title":"Hypertension, seizures, and epilepsy: a review on pathophysiology and management.","volume":"40","author":"Gasparini","year":"2019","journal-title":"Neurol Sci"},{"key":"noi220064r8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.brainresbull.2019.05.002","article-title":"Losartan inhibits development of spontaneous recurrent seizures by preventing astrocyte activation and attenuating blood-brain barrier permeability following pilocarpine-induced status epilepticus.","volume":"149","author":"Hong","year":"2019","journal-title":"Brain Res Bull"},{"issue":"6","key":"noi220064r9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10571-015-0278-3","article-title":"Long-term treatment with losartan attenuates seizure activity and neuronal damage without affecting behavioral changes in a model of co-morbid hypertension and epilepsy.","volume":"36","author":"Tchekalarova","year":"2016","journal-title":"Cell Mol Neurobiol"},{"issue":"6","key":"noi220064r10","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/ana.v75.6","article-title":"Losartan prevents acquired epilepsy via TGF-\u00df signaling suppression.","volume":"75","author":"Bar-Klein","year":"2014","journal-title":"Ann Neurol"},{"issue":"2","key":"noi220064r11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/08037050600771583","article-title":"Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE)\u2014a review.","volume":"15","author":"Zanchetti","year":"2006","journal-title":"Blood Press"},{"issue":"9","key":"noi220064r12","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.amjcard.2011.12.025","article-title":"Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study).","volume":"109","author":"Shiraishi","year":"2012","journal-title":"Am J Cardiol"},{"issue":"10","key":"noi220064r13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5414\/CP203320","article-title":"Basic characteristics and representativeness of the German Disease Analyzer database.","volume":"56","author":"Rathmann","year":"2018","journal-title":"Int J Clin Pharmacol Ther"},{"key":"noi220064r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108393","article-title":"Epilepsy is associated with an increased incidence of heart failure diagnoses.","volume":"125","author":"Doege","year":"2021","journal-title":"Epilepsy Behav"},{"key":"noi220064r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107857","article-title":"Physical and mental health comorbidities of patients with epilepsy in Germany\u2014a retrospective cohort study.","volume":"117","author":"Uepping","year":"2021","journal-title":"Epilepsy Behav"},{"key":"noi220064r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107502","article-title":"Association between antiseizure medication use and risk of urinary tract infection: a case-control study.","volume":"115","author":"Heidemann","year":"2021","journal-title":"Epilepsy Behav"},{"key":"noi220064r17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.yebeh.2018.10.035","article-title":"Incidence of epilepsy and associated factors in elderly patients in Germany.","volume":"90","author":"Jacob","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"2","key":"noi220064r18","first-page":"120","article-title":"Good Practice of Secondary Data Analysis (GPS): guidelines and recommendations.","volume":"77","author":"Swart","year":"2015","journal-title":"Gesundheitswesen"},{"issue":"33","key":"noi220064r19","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension.","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"2","key":"noi220064r20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/jamaneurol.2021.4584","article-title":"Association between antiseizure drug monotherapy and mortality for patients with poststroke epilepsy.","volume":"79","author":"Larsson","year":"2022","journal-title":"JAMA Neurol"},{"issue":"3","key":"noi220064r21","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac010","article-title":"Bi-directional associations of epilepsy with dementia and Alzheimer\u2019s disease: a systematic review and meta-analysis of longitudinal studies.","volume":"51","author":"Dun","year":"2022","journal-title":"Age Ageing"},{"issue":"2","key":"noi220064r22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.21618","article-title":"Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis.","volume":"3","author":"Wei","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"noi220064r23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030726","article-title":"Role of the angiotensin pathway and its target therapy in epilepsy management.","volume":"20","author":"Krasniqi","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"6","key":"noi220064r24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1042\/CS20201296","article-title":"Brain angiotensin system: a new promise in the management of epilepsy?","volume":"135","author":"Ramos","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"noi220064r25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.mcn.2015.02.014","article-title":"Angiotensin II and its receptor in activated microglia enhanced neuronal loss and cognitive impairment following pilocarpine-induced status epilepticus.","volume":"65","author":"Sun","year":"2015","journal-title":"Mol Cell Neurosci"},{"issue":"4","key":"noi220064r26","doi-asserted-by":"publisher","first-page":"828","DOI":"10.14336\/AD.2020.0222","article-title":"TGF-\u00df signaling: a therapeutic target to reinstate regenerative plasticity in vascular dementia?","volume":"11","author":"Kandasamy","year":"2020","journal-title":"Aging Dis"},{"key":"noi220064r27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.eplepsyres.2018.08.004","article-title":"Altered transforming growth factor beta\/SMAD3 signalling in patients with hippocampal sclerosis.","volume":"146","author":"Paul","year":"2018","journal-title":"Epilepsy Res"},{"issue":"4","key":"noi220064r28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/npp.2010.225","article-title":"Angiotensin II AT1 receptor blockade ameliorates brain inflammation.","volume":"36","author":"Benicky","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"noi220064r29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.brainres.2018.05.027","article-title":"The angiotensin II type I receptor antagonist losartan retards amygdala kindling-induced epileptogenesis.","volume":"1694","author":"Nozaki","year":"2018","journal-title":"Brain Res"},{"key":"noi220064r30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pbb.2014.10.005","article-title":"Antiepileptogenic and neuroprotective effects of losartan in kainate model of temporal lobe epilepsy.","volume":"127","author":"Tchekalarova","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"issue":"6","key":"noi220064r31","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/08037051.2020.1779582","article-title":"Antihypertensive prescription patterns and cardiovascular risk in patients with newly diagnosed hypertension\u2014an analysis of statutory health insurance data in Germany.","volume":"29","author":"Beger","year":"2020","journal-title":"Blood Press"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2797021\/jamaneurology_doege_2022_oi_220064_1670426926.9997.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T11:01:12Z","timestamp":1670842872000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2797021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2022.3413","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742368464.793596041","asserted-by":"object"}]},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}